II
MYGN icon

Inspire Investing’s Myriad Genetics MYGN Stock Holding History

Inspire Investing’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$684K Buy
119,717
+3,991
+3% +$18.1K 0.03% 614
2026
Q1 		$521K Buy
115,726
+25,455
+28% +$133K 0.03% 518
2025
Q4 		$555K Buy
90,271
+10,585
+13% +$76.8K 0.05% 312
2025
Q3 		$576K Sell
79,686
-4,834
-6% -$28.7K 0.06% 262
2025
Q2 		$449K Buy
84,520
+40,793
+93% +$241K 0.05% 319
2025
Q1 		$388K Buy
43,727
+12,354
+39% +$148K 0.05% 322
2024
Q4 		$430K Buy
31,373
+14,406
+85% +$266K 0.05% 348
2024
Q3 		$465K Buy
16,967
+2,538
+18% +$68.7K 0.05% 314
2024
Q2 		$353K Sell
14,429
-2,226
-13% -$48.8K 0.04% 493
2024
Q1 		$355K Sell
16,655
-3,559
-18% -$76.5K 0.04% 759
2023
Q4 		$387K Buy
20,214
+1,212
+6% +$21K 0.04% 440
2023
Q3 		$305K Buy
19,002
+5,505
+41% +$105K 0.04% 754
2023
Q2 		$313K Buy
13,497
+1,711
+15% +$37.3K 0.04% 695
2023
Q1 		$274K Sell
11,786
-4,992
-30% -$101K 0.03% 518
2022
Q4 		$243K Buy
16,778
+6,149
+58% +$115K 0.03% 350
2022
Q3 		$203K Sell
10,629
-990
-9% -$22.7K 0.03% 742
2022
Q2 		$211K Buy
11,619
+2,241
+24% +$46.5K 0.03% 675
2022
Q1 		$236K Buy
9,378
+503
+6% +$12.9K 0.03% 513
2021
Q4 		$245K Buy
8,875
+1,879
+27% +$54.4K 0.03% 731
2021
Q3 		$226K Sell
6,996
-1,188
-15% -$39.5K 0.03% 683
2021
Q2 		$250K Buy
8,184
+248
+3% +$7.17K 0.03% 564
2021
Q1 		$242K Sell
7,936
-4,092
-34% -$116K 0.04% 563
2020
Q4 		$238K Sell
12,028
-608
-5% -$9.82K 0.05% 553
2020
Q3 		$165K Buy
+12,636
New +$160K 0.05% 396
2018
Q1 		– Sell
-1,617
Closed -$56K – 511
2017
Q4 		$56K Buy
+1,617
New +$54.6K 0.05% 558

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Inspire Investing's MYGN Position: Q2 2026 in Review

Inspire Investing increased its Myriad Genetics (MYGN) stake by 3.4% in Q2 2026, buying an estimated $18.1K and bringing the position to 119,717 shares worth $684K. The position accounts for 0.03% of the portfolio, ranked #614.

Inspire Investing first reported a position in MYGN in Q4 2017 and has held it in 25 quarters since. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Inspire Investing held 119,717 shares of Myriad Genetics worth $684K as of Q2 2026.
  • Inspire Investing bought 3,991 Myriad Genetics shares in Q2 2026, an estimated $18.1K.
  • Myriad Genetics made up 0.03% of Inspire Investing's portfolio in Q2 2026, its #614 holding.
  • Inspire Investing first reported a position in Myriad Genetics in Q4 2017 and has held it in 25 quarters since.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Inspire Investing's 13F filing for Q2 2026, filed 12 Aug 2026.